Move at the speed of experience.

Optimizing commercial development focused in rare diseases to drive value, accelerate time to market and maximize revenue potential.

Engage an experienced and cross-functional team able to be fully operational within days.

Employ a holistic approach spanning strategy through execution.

Scale your commercial organization while simultaneously working to prepare the market.

Mitigate risk associated with a suboptimal launch.

Our Operational Philosophy.

ReCiPe™ is designed to rapidly accelerate commercialization for clinical-stage biotech companies through the creation of strategic efficiencies and excellence in execution. Utilizing an integrated approach beginning with evidence-based insights through to strategy development and implementation, ReCiPe™ can be applied from phase II to phase III of clinical development.

Strategic excellence.

Expert execution.

Optimize Commercial Strategy + Execution Assess Market Opportunity Maximize Asset Valuation

"Efficiency and results are the natural
outcome of expertise and practical
knowledge."

Christina Ansted, MPH, CCMEP
Chief Executive Officer

Optimize Commercial Strategy + Execution Assess Market Opportunity Maximize Asset Valuation
  • Rare Disease and Gene Therapy
  • Unbiased Commercial Viability
  • Pre-Clinical - Phase III
  • Commercial Development
  • Valuation for Potential Investors
  • Commercial Operations
  • Strategic Market Preparation
  • Market and Patient Access
  • Payer Value Story Development
  • Patient Services
  • KOL/Key Investigator Development
  • Patient Identification/Diagnostics
  • Market Analytics
  • Vendor Management
  • Stakeholder Engagement
  • Patient Journey